Non-exclusive pharmaceutical rebate agreement for Glatiramer acetate PEN
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. AM-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Glatirameracetat in der Darreichungsform PEN (ATC-Code nach WHO: L03AX13)
Opportunity Score
Why this score?
Opportunity
20 / 100
Complexity
30 / 100
Risk factors
The demanded quantity is unknown and not guaranteed. It depends on patient numbers, prescription behavior, and pharmacy...
AOK PLUS reserves the right to terminate the open-house model prematurely if exclusive agreements are made (typically w...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jun 30, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2027
- Supply of Glatiramer acetate in PEN dosage form (ATC L03AX13) to patients insured by AOK PLUS in Saxony and Thuringia
- Non-exclusive rebate agreement; no guaranteed purchase volumes or exclusivity
Show full summary
Non-exclusive pharmaceutical rebate agreement (Rabattvereinbarung) under §130a Abs.8 SGB V via an open-house model for Glatiramer acetate in PEN dosage form (ATC L03AX13), managed by AOK PLUS for Saxony and Thuringia. Open to all qualified pharmaceutical entrepreneurs; no exclusivity, no guaranteed volumes, and no traditional award criteria. The contract ends 30.06.2027. First submission deadline: 02.06.2025; further rolling deadlines available. Detailed terms and discount amounts are confidential and available only after access to the DTVP project room. This publication is for transparency only and not a formal procurement procedure.
Risks
The demanded quantity is unknown and not guaranteed. It depends on patient numbers, prescription behavior, and pharmacy...
AOK PLUS reserves the right to terminate the open-house model prematurely if exclusive agreements are made (typically w...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4 Abs.18 AMG with respect to the offered medicinal products
- Must accept the fixed terms of the rebate agreement; no individual negotiations
Eligibility
- Must submit a declaration of no grounds for exclusion (§§123,124 GWB) and a declaration regarding Russia sanctions (EU Reg. 833/2014)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive pharmaceutical rebate agreement for Glatiramer acetate PEN
Non-exclusive rebate agreement for the supply of Glatiramer acetate in PEN formulation to AOK PLUS for patients in Saxony and Thuringia. Open-house model; no minimum volume guaranteed; no exclusivity; contract ends 30.06.2027.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. AM-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Glatirameracetat in der Darreichungsform PEN (ATC-Code nach WHO: L03AX13)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 17 Apr 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 255277-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
20 / 100
Complexity
30 / 100
Risk factors
The demanded quantity is unknown and not guaranteed. It depends on patient numbers, prescription behavior, and pharmacy...
AOK PLUS reserves the right to terminate the open-house model prematurely if exclusive agreements are made (typically w...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications